Vivace Therapeutics

Vivace Therapeutics is an oncology-focused small molecule drug discovery and development company based in San Mateo, California. Founded in 2016, the company focuses exclusively on the Hippo-YAP signaling pathway — a key regulator of cell proliferation, programmed cell death, and organ size — which is dysregulated across a wide range of cancers including mesothelioma, meningioma, schwannoma, lung, breast, and hepatocellular carcinoma. Vivace's lead program, VT3989, is a first-in-class YAP/TEAD palmitoylation inhibitor that has demonstrated clinical proof-of-concept in Phase I/II trials for refractory mesothelioma, receiving FDA Fast Track and Orphan Drug designations. The company has raised over $105 million across Series A through D financings and operates with a capital-efficient model leveraging scientific talent across the US and China.